A U.S. Court of Appeals for the Federal Circuit panel on Tuesday confirmed that a number of biotechnology patents filed by Pacific Biosciences were invalid, upholding findings reached in March 2020 by the U.S. District of Delaware's final pre-pandemic jury, which found in favor of a British-based pharma company.